ISAL 2019 | NOX2: a potential immune checkpoint for inhibition in AML

Name: NOX2: a potential immune checkpoint for inhibition in AML
Uploaded: 2019-02-25T00:00:00.000Z
Duration: 3 min 21 s
Description: Myeloid cell NADPH oxidase isoform 2 (NOX2) generates ROS, and recent research indicates that it is a targetable immune checkpoint in cancer. Here, Anna Martner, PhD, of the University of Gothenburg, Gothenburg, Sweden, discusses her group's recent research into NOX2 inhibitors in KRAS-induced murine models of myeloproliferative disease.

Anna Martner • 25 Feb 2019

ISAL 2019

Acute Myeloid Leukemia Leukemia Checkpoint inhibitors

Myeloid cell NADPH oxidase isoform 2 (NOX2) generates ROS, and recent research indicates that it is a targetable immune checkpoint in cancer. Here, Anna Martner, PhD, of the University of Gothenburg, Gothenburg, Sweden, discusses her group’s recent research into NOX2 inhibitors in KRAS-induced murine models of myeloproliferative disease.